Compound E, chemically designated as 209986-17-4 (CAS), represents a significant study within the field of Alzheimer's illness research. This γ-secretase blocking agent was initially developed as a potential therapeutic treatment aimed at reducing the production of amyloid-beta peptides, which are believed to be central contributors to the formati